Kenneth Galbraith, Zymeworks CEO
As its slide stretches into a second year, Zymeworks faces takeover bid
Zymeworks’ new CEO Kenneth Galbraith has vastly remade the nearly 20-year-old biotech in the few short months he’s run the show. But his efforts to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
